The role of Tα1 on the infective patients after hematopoietic stem cell transplantation.

Ding JH, Wang LL, Chen Z, Wang J, Yu ZP, Zhao G, Chen BA

International journal of hematology10 Jan 2013Cited by 14 (Europe PMC)

PMID23307511DOI10.1007/s12185-012-1208-5PepBankPUB-23307511

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, 2 weeks of thymosin α1 raised concentrations of IFN-γ, IL-2, IL-4, IL-10 and IL-12 after 1 month in the treatment group.
In plain wordsIn transplant patients with infection, thymosin α1 was followed by higher levels of several immune signalling proteins after one month.
Peptide
Thymosin alpha-1
Outcome
IncreaseCytokine concentrations (IFN-γ, IL-2, IL-4, IL-10, IL-12) at 1 month
Study
n = 8
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
When Tα1 was administered for 2 weeks, the concentrations of these cytokines were increased after 1 month in the treatment group.
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751101
02HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, IFN-γ rose more with thymosin α1 than in the control group.
In plain wordsIn transplant patients with infection, thymosin α1 raised IFN-γ more than in the control group.
Peptide
Thymosin alpha-1
Outcome
IncreaseIFN-γ concentration
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751102
03HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, IL-2 rose more with thymosin α1 than in the control group.
In plain wordsIn transplant patients with infection, thymosin α1 raised IL-2 more than in the control group.
Peptide
Thymosin alpha-1
Outcome
IncreaseIL-2 concentration
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751103
04HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, IL-10 rose more with thymosin α1 than in the control group.
In plain wordsIn transplant patients with infection, thymosin α1 raised IL-10 more than in the control group.
Peptide
Thymosin alpha-1
Outcome
IncreaseIL-10 concentration
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751104
05HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, IL-12 rose more with thymosin α1 than in the control group.
In plain wordsIn transplant patients with infection, thymosin α1 raised IL-12 more than in the control group.
Peptide
Thymosin alpha-1
Outcome
IncreaseIL-12 concentration
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751105
06HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, CD3+ T cell levels did not differ significantly between thymosin α1 and control groups.
In plain wordsIn transplant patients with infection, thymosin α1 did not change CD3+ T cell levels compared with the control group.
Peptide
Thymosin alpha-1
Outcome
No significant changeCD3+ T cell level
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751106
07HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, CD4+ T cell levels did not differ significantly between thymosin α1 and control groups.
In plain wordsIn transplant patients with infection, thymosin α1 did not change CD4+ T cell levels compared with the control group.
Peptide
Thymosin alpha-1
Outcome
No significant changeCD4+ T cell level
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751107
08HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, CD8+ T cell levels did not differ significantly between thymosin α1 and control groups.
In plain wordsIn transplant patients with infection, thymosin α1 did not change CD8+ T cell levels compared with the control group.
Peptide
Thymosin alpha-1
Outcome
No significant changeCD8+ T cell level
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751108
09HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, the CD4+/CD8+ ratio did not differ significantly between thymosin α1 and control groups.
In plain wordsIn transplant patients with infection, thymosin α1 did not change the CD4+/CD8+ ratio compared with the control group.
Peptide
Thymosin alpha-1
Outcome
No significant changeCD4+/CD8+ ratio
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751109
10HumanRandomized controlled trialEfficacy outcome
In recipients of hematopoietic stem cell transplantation with infection, CD4+/CD25+ regulatory T cells did not differ significantly between thymosin α1 and control groups.
In plain wordsIn transplant patients with infection, thymosin α1 did not change regulatory T cells compared with the control group.
Peptide
Thymosin alpha-1
Outcome
No significant changeCD4+/CD25+ regulatory T cells
Study
n = 8
Comparator
Control group
Outcome group
Immune response · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Interestingly, the levels of IFN-γ, IL-2, IL-10, and IL-12 were increased in the treatment group more than those in the control group, whereas there were no significant differences between the treatment and control group in the levels of CD3(+), CD4(+), and CD8(+) T cells, or in CD4(+)/CD8(+) or CD4…
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751110
11HumanRandomized controlled trialSafety outcome
In recipients of hematopoietic stem cell transplantation with infection, thymosin α1 administration did not cause acute or chronic graft versus host disease.
In plain wordsIn transplant patients with infection, thymosin α1 did not cause graft versus host disease.
Peptide
Thymosin alpha-1
Outcome
No significant changeAcute or chronic graft versus host disease
Study
n = 8
Outcome group
Adverse events · Immune and inflammation
Studied dose
Dose not stated · 2 weeksAs given in this study (human).
Source sentences
Summary
Notably, Tα1 administration did not cause acute or chronic graft versus host disease (GVHD).
2 context sentences(design, population, supporting numbers)
Summary · context
Eight patients were enrolled in our study, including seven allo-HSCT patients and one auto-HSCT patient.
Summary · context
These patients were allocated randomly into the treatment group (four cases) and control group (four cases).
Report a problemFND-2330751111

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
10 Oct 2026, 08:55 UTC
Study results updated
Version 2
9 Oct 2026, 03:03 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:02 UTC
First added · source update from Europe PMC

The role of Tα1 on the infective patients after hematopoietic stem cell transplantation.

Summary

Results from this study11

Version history

Subjects

Publication types

MeSH terms